877876-61-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-(4'-bromophenyl)-3-hydroxypropanenitrile is used as an intermediate in the synthesis of various pharmaceutical compounds due to its unique structural properties and potential for creating more complex organic molecules. Its versatility as a building block allows for the development of new drugs with specific therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, (R)-3-(4'-bromophenyl)-3-hydroxypropanenitrile is utilized as a starting material for the creation of novel agrochemicals. Its structural features make it a promising candidate for the development of new pesticides, herbicides, and other agricultural chemicals that can improve crop yields and protect against pests.
Used in Organic Chemistry Research:
(R)-3-(4'-bromophenyl)-3-hydroxypropanenitrile is also used as a valuable tool in organic chemistry research. Its stereochemistry and structural properties provide opportunities for chemists to explore new reactions and develop innovative synthetic methods, contributing to the advancement of chemical science.

Upstream product

• 1122-91-4 4-bromo-benzaldehyde 
• 75-05-8 acetonitrile 
• 143-33-9 sodium cyanide 
• 148684-05-3 2-(4-bromophenyl)oxirane 
• 4592-94-3 3-(4-bromophenyl)-3-oxopropanenitrile 

Relevant academic research and scientific papers

Direct Catalytic Asymmetric Addition of Alkylnitriles to Aldehydes with Designed Nickel–Carbene Complexes

A direct catalytic asymmetric addition of acetonitrile to aldehydes that realizes over 90 % ee is the ultimate challenge in alkylnitrile addition chemistry. Herein, we report achieving high enantioselectivity by the strategic use of a sterically demanding NiII pincer carbene complex, which afforded highly enantioenriched β-hydroxynitriles. This highly atom-economical process paves the way for exploiting inexpensive acetonitrile as a promising C2 building block in a practical synthetic toolbox for asymmetric catalysis.

Facile construction of functionalized periodic mesoporous organosilica for Ir-catalyzed enantioselective reduction of α-cyanoacetophenones and α-nitroacetophenones

A facile method to construct chiral organoiridium-functionalized periodic mesoporous organosilica is developed. The heterogeneous catalyst displays excellent catalytic efficiency in the enantioselective reduction of α-cyanoacetophenones and α-nitroacetoph

Preparative access to medicinal chemistry related chiral alcohols using carbonyl reductase technology

Libraries of highly enantioenriched secondary alcohols in both enantiomeric forms were synthesised by enzymatic reduction of their parent ketones using selectAZyme carbonyl reductase (CRED) technology. Commercially available CREDs were able to reduce a range of substrate classes efficiently and with very high enantioselectivity. Matching substrate classes to small subsets of CREDs enabled the fast development of preparative bioreductions and the rapid generation of 100-1500 mg samples of chiral alcohols in typically >95% ee and the majority in ≥99.0% ee. The conditions for small scale synthesis were then scaled up to 0.5 kg to deliver one of the chiral alcohols, (S)-1-(4-bromophenyl)-2-chloroethanol, in 99.8% ee and 91% isolated yield.

Asymmetric reduction of β-ketonitriles with a recombinant carbonyl reductase and enzymatic transformation to optically pure β-hydroxy carboxylic acids

α-Ethylation is concomitant with the reduction of aromatic β-ketonitriles catalyzed by whole-cell biocatalysts. Use of isolated carbonyl reductase has completely eliminated this competing reaction. (R)-β-Hydroxy nitriles were obtained via a reduction cata

BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of tricyclic compounds that are useful as such agents.